Existing investors Kalaari Capital, Sabre Partners and Aarin Capital also participated, it said in a statement.
Vyome Biosciences is developing medicines for treating skin diseases caused by resistant microbes.
"We will utilise these funds predominantly to advance the clinical development of our lead product VB 1953," its co-founder and Chief Executive Venkateswarlu Nelabhotla said.
The company will continue to advance the development of other proprietary products in the pre-clinical stage, he added.
"The support from leading global and leading life investors and the continued support from our largest existing shareholders validates our company's strategy, science and development programs," he added.
The website offers 75 'experiences', including meeting celebrities and driving a luxury car.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
